Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases

Details for Australian Patent Application No. 2005205915 (hide)

Owner Novartis AG

Inventors Furet, Pascal; Bold, Guido; Masuya, Keiichi; Imbach, Patricia; Floersheimer, Andreas; Schoepfer, Joseph; MartinyBaron, Georg

Agent Davies Collison Cave

Pub. Number AU-B-2005205915

PCT Pub. Number WO2005/070431

Priority 60/538,220 22.01.04 US

Filing date 21 January 2005

Wipo publication date 4 August 2005

Acceptance publication date 21 May 2009

International Classifications

A61K 31/505 (2006.01) - Pyrimidines

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

Event Publications

20 July 2006 PCT application entered the National Phase

  PCT publication WO2005/070431 Priority application(s): WO2005/070431

21 May 2009 Application Accepted

  Published as AU-B-2005205915

17 September 2009 Standard Patent Sealed

18 August 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005205917-Use of low-dose erythropoietin for the treatment of acute or chronic kidney failure and for the treatment of wounds

2005205914-Combination of organic compounds